A Prospective, Active Control Open Label, Multicentre Randomized Clinical Trial for Comparison Between BioMime Sirolimus Eluting Stent of Meril Life Sciences and Xience Everolimus Eluting Stent of Abbott Vascular Inc. to Evaluate Efficacy and Safety in Coronary Artery Disease.
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 09 Aug 2019
Price : $35 *
At a glance
- Drugs Sirolimus (Primary) ; Everolimus
- Indications Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms meriT-V
- Sponsors Meril Life Sciences
- 25 Sep 2018 Primary endpoint (To assess in-stent Late Lumen Loss) has been met, according to the results presented at the 30th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics
- 25 Sep 2018 Results assessing 12-month clinical outcomes, presented at the 30th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics
- 03 Apr 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2019.